Scout Investments Inc. increased its holdings in shares of Humana Inc (NYSE:HUM) by 440.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 79,217 shares of the insurance provider’s stock after purchasing an additional 64,555 shares during the quarter. Scout Investments Inc. owned 0.06% of Humana worth $21,016,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in HUM. BlackRock Inc. lifted its holdings in Humana by 1.6% in the first quarter. BlackRock Inc. now owns 12,190,049 shares of the insurance provider’s stock valued at $3,242,553,000 after acquiring an additional 186,997 shares during the period. Janus Henderson Group PLC lifted its holdings in Humana by 3.5% in the first quarter. Janus Henderson Group PLC now owns 3,596,204 shares of the insurance provider’s stock valued at $956,594,000 after acquiring an additional 120,905 shares during the period. Geode Capital Management LLC lifted its holdings in Humana by 8.3% in the fourth quarter. Geode Capital Management LLC now owns 1,773,576 shares of the insurance provider’s stock valued at $507,198,000 after acquiring an additional 135,776 shares during the period. Northern Trust Corp lifted its holdings in Humana by 0.5% in the first quarter. Northern Trust Corp now owns 1,743,519 shares of the insurance provider’s stock valued at $463,775,000 after acquiring an additional 8,221 shares during the period. Finally, Norges Bank bought a new position in Humana in the fourth quarter valued at about $402,117,000. 92.62% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE:HUM traded down $1.65 during trading on Thursday, hitting $274.44. The company had a trading volume of 782,517 shares, compared to its average volume of 1,321,036. The company has a market cap of $38.04 billion, a PE ratio of 18.86, a price-to-earnings-growth ratio of 1.23 and a beta of 0.87. Humana Inc has a one year low of $225.65 and a one year high of $355.88. The stock has a fifty day moving average price of $265.82. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.65 and a current ratio of 1.65.
HUM has been the subject of a number of analyst reports. Morgan Stanley set a $207.00 price target on Alibaba Group and gave the stock a “buy” rating in a research report on Friday, July 12th. Zacks Investment Research cut Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. ValuEngine upgraded Valmont Industries from a “sell” rating to a “hold” rating in a report on Friday, July 12th. Barclays set a $24.00 price target on Tenet Healthcare and gave the company a “hold” rating in a report on Wednesday, April 17th. Finally, SunTrust Banks raised their price target on Markel to $1,100.00 and gave the company a “hold” rating in a report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $336.42.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: What is the CBOE Russell 2000® Volatility Index?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.